Lilly Sued Six Sellers Over Retatrutide. The Real Defendant Is Three Words.

On August 12th, Eli Lilly sued six companies over retatrutide. Read the complaint and you find the case is not really about retatrutide at all. It is about three words that this entire market, including the shelf you probably buy from, has been leaning on for years: research use only.

If you have spent any time on peptide sites, you know the phrase. It sits in the footer, on the vial, in the checkout terms. It is the sentence that lets a product that looks like medicine be sold as something else. Lilly's argument is that when a seller says those words and everyone involved knows what the buyer is going to do, the words stop being a disclaimer and start being evidence.

What actually happened

Lilly filed six suits against Aesthetic Envy Cosmetic Centers, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide Co. Lilly alleges the companies sold black market versions of retatrutide, and that some of them marketed those products as being for research use only when they were in fact intended for people to inject. It further alleges the material was frequently sourced from unregulated foreign manufacturers.

These are allegations. Nobody has been found liable of anything. Legendary Peptides declined to comment and the other five had not responded when the first reports ran.

The suits are not a surprise so much as an escalation. Lilly has now filed more than 130 actions against compounders and wellness centres, and says it has flagged over 200 individuals and entities to the FDA, the Department of Justice, state attorneys general, law enforcement, and professional licensing boards. In April a federal court cleared its unfair competition case against the telehealth company Mochi Health to proceed, on the second attempt.

The part people keep getting wrong

Retatrutide is not an approved drug that is being copied badly. It is not approved anywhere on earth. No regulator on any continent has cleared it, and Lilly does not plan to even submit an FDA application until next year. It is still in Phase 3 trials, which is the stage where a drug is being tested in large numbers of humans precisely because nobody yet knows the full answer on safety and effect size.

That is a different situation from compounded tirzepatide, which is where most of the coverage has been. Tirzepatide is approved, it went into shortage, compounders were permitted to make it during the shortage, the shortage ended in December 2024, and the FDA told them to stop. That is a fight about the edges of a legal exception.

Retatrutide has no exception to sit inside. The FDA's position is that selling unapproved retatrutide to consumers is illegal and that it cannot lawfully be compounded at all. There is no shortage window, because there is no approved product to be short of.

Why the label does not do the work

Here is the thing about research use only, and it is worth understanding whichever side of the counter you are on. It is not a magic phrase. It describes an intended use, and intent is something a court infers from the whole picture rather than reading off a sticker.

If a product is sold in a dose that matches a human titration schedule, in a vial sized for a person, next to marketing copy about appetite and body composition, to a customer with no lab and no institutional affiliation, the sticker is not the strongest evidence in the room. Everything around it is. A seller can write the words in good faith and still be describing a transaction that does not match them.

I am not a lawyer and this is not legal advice. But you do not need a law degree to notice that a disclaimer contradicted by every other element of the sale is a disclaimer under strain.

Where this leaves us, uncomfortably

Now the part I would rather skip.

This publication carries a compound reference for retatrutide. That page includes a dosing table with reported figures, one of them a titration range read off the Phase 3 protocol. Every row is sourced and attributed, which is the standard I hold everyone else to. It is still a dosing table for a drug that is not approved anywhere and that the FDA says cannot be lawfully sold to consumers for use.

I do not think reporting what published protocols say is the same act as selling the compound. Those are genuinely different things, and I would defend the difference. But I am not going to pretend the distinction is so obvious that it needs no defending, on the same page where I argue that context beats labels. That would be the exact move I just spent four paragraphs criticising.

So, two things I can tell you honestly. The supplier this publication belongs to does not list retatrutide or tirzepatide at all, and you can check that yourself in the catalogue rather than taking my word for it. And I am reviewing whether a dosing table is the right shape for a compound in this specific position, where the legal question is not at the edges but at the centre. If that review changes something, it will show up in the corrections log like everything else.

What to actually take from this

If you are reading about this because you buy peptides, the useful takeaway is not "retatrutide is banned now." It is narrower and more durable than that.

The legal status of a compound is a separate axis from its evidence. A compound can be well studied and unapproved. It can be approved and thinly studied for the thing you care about. Retatrutide currently sits in a place where the evidence is genuinely interesting, the Phase 3 programme is real and ongoing, and the commercial situation around it is a mess. Those facts do not cancel each other out, and a seller who tells you only the first one is selling you a partial picture.

And if a product's legality depends entirely on a sentence in the footer, that is worth noticing. Not because the sentence is necessarily false, but because a claim that fragile is the kind this publication exists to look at twice.

The claim is not the compound. It turns out the disclaimer is not the transaction either.

A reader pushed back on this one, and the pushback was better than the piece: if retatrutide is not approved and Lilly has never been allowed to sell it, how can there be an injury at all? It turns out there is a real answer, and it does not involve lost sales. That is part two.